Affimed - Gilde Healthcare


Heidelberg, Germany
Oncology therapeutics based on the innate immune system
Since: 2022

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives.

Gilde followed Affimed’s development for many years and became convinced about the potential of its technology platform and immune oncology product pipeline. By anchoring an upsized public offering of $103.5 million in April 2022, we enabled a transformational financing in a turbulent market environment, reflecting our impactful, hands-on investment strategy.